XML 24 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Equity - BRL (R$)
R$ in Thousands
Total
Share capital
Equity instrument granted
Capital reserve
Treasury shares
Revaluation reserve on subsidiaries
Legal Reserves
Investments statutory reserve
Accumulated other comprehensive income
Cumulative translation adjustments
Retained earnings
Additional dividends to the minimum mandatory dividends
Shareholders of the Company
Non-controlling interests in subsidiaries
Beginning balance at Dec. 31, 2019 R$ 9,835,175 R$ 5,171,752 R$ 11,970 R$ 542,400 R$ (485,383) R$ 4,522 R$ 705,341 R$ 3,290,073 R$ (146,317) R$ 102,427   R$ 261,470 R$ 9,458,255 R$ 376,920
Net income for the year 927,697                   R$ 893,383   893,383 34,314
Other comprehensive income:                            
Actuarial losses of post-employment benefits, net of income taxes (16,887)                          
Currency translation of foreign subsidiaries, including the effect of net investments hedge 129,169                          
Other comprehensive income (200,799)               (318,673) 129,169     (189,504) (11,295)
Total comprehensive income for the year 726,898               (318,673) 129,169 893,383   703,879 23,019
Issuance of shares related to the subscription warrants - indemnification 54,763     54,763                 54,763  
Stock plan (6,799)     (3,114) (3,685)               (6,799)  
Equity instrument granted 10,434   10,434                   10,434  
Income and social contribution taxes on realization of revaluation reserve of subsidiaries           (185)         185      
Transfer to statutory reserve               (774)     774      
Shareholder transaction – changes of investments                     42   42 (42)
Dividends attributable to non-controlling interests (24,379)                       (1,001) (23,378)
Approval of additional dividends by the Ordinary General Meeting (261,470)                     (261,470) (261,470)  
Allocation of net income:                            
Legal reserve             44,669       (44,669)      
Investments statutory reserve               368,966     (368,966)      
Proposed dividends (424,357)                   (479,748) 55,391 (424,357)  
Ending balance at Dec. 31, 2020 9,910,265 5,171,752 22,404 594,049 (489,068) 4,337 750,010 3,658,265 (464,990) 231,596   55,391 9,533,746 376,519 [1]
Net income for the year 883,878                   850,463   850,463 33,415 [1]
Other comprehensive income:                            
Actuarial losses of post-employment benefits, net of income taxes 46,610                          
Currency translation of foreign subsidiaries, including the effect of net investments hedge 73,049                          
Other comprehensive income 126,933               42,852 73,049     115,901 11,032 [1]
Total comprehensive income for the year 1,010,811               42,852 73,049 850,463   966,364 44,447 [1]
Issuance of shares related to the subscription warrants - indemnification 1,819     1,819                 1,819  
Equity instrument granted 12,895   11,639 613 643               12,895  
Realization of revaluation reserve of subsidiaries           (183)         183      
Dividends prescribed 11,816                   10,487   10,487 1,329 [1]
Gains arising from payments of fixed dividends to preferred shares of subsidiaries                     971   971 (971) [1]
Shareholder transaction – changes of investments               11,641     (11,641)      
Dividends attributable to non-controlling interests (19,005)                         (19,005) [1]
Approval of additional dividends by the Ordinary General Meeting (55,391)                     (55,391) (55,391)  
Allocation of net income:                            
Legal reserve             42,523       (42,523)      
Investments statutory reserve               403,970     (403,970)      
Proposed dividends (185,896)                   (185,896)   (185,896)  
Intermediary dividends (218,074)                   (218,074)   (218,074)  
Ending balance at Dec. 31, 2021 10,469,240 5,171,752 34,043 596,481 (488,425) 4,154 792,533 4,073,876 (422,138) 304,645 [2]     10,066,921 402,319 [1]
Net income for the year 1,840,069                   1,800,839   1,800,839 39,230 [1]
Other comprehensive income:                            
Actuarial losses of post-employment benefits, net of income taxes (165)                          
Currency translation of foreign subsidiaries, including the effect of net investments hedge (304,645)                          
Other comprehensive income 297,670               602,112 (304,645) [2]     297,467 203 [1]
Total comprehensive income for the year 2,137,739               602,112 R$ (304,645) [2] 1,800,839   2,098,306 39,433 [1]
Issuance of shares related to the subscription warrants - indemnification 941     941                 941  
Equity instrument granted 20,734   9,944 2,039 8,751               20,734  
Realization of revaluation reserve of subsidiaries           (179)         179      
Dividends prescribed 2,948                   2,948   2,948  
Shareholder transaction – changes of investments (6,567)             (6)     286   280 (6,847) [1]
Changes in ownership interests in subsidiaries (2,423)                       985 (2,423) [1]
Capital increase attributable to non-controlling interests 35,182                         35,182 [1]
Dividends attributable to non-controlling interests (1,437)                         (1,437) [1]
Allocation of net income:                            
Legal reserve             90,042       (90,042)      
Investments statutory reserve               1,154,691     (1,154,691)      
Additional minimum mandatory dividend (R$ 0.03 per share) (31,385)                   (35,385)   (31,385)  
Additional dividends to the minimum mandatory dividends (R$ 0.07 per share) (78,130)                   (78,130) R$ 78,130    
Interest on capital (R$ 0.41 per share) (450,004)                   R$ (450,004)   (450,004)  
Ending balance at Dec. 31, 2022 R$ 12,174,968 R$ 5,171,752 R$ 43,987 R$ 599,461 R$ (479,674) R$ 3,975 R$ 822,575 R$ 5,228,561 R$ 179,974       R$ 11,708,741 R$ 466,227 [1]
[1] Are substantially represented by non-controlling shareholders of Iconic.
[2] Cumulative translation adjustment from discontinued operation. The accumulated effects were reclassified to income as a result of the sale of Oxiteno (see note 4.b).